PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss
PMGC Holdings has entered into a non-binding term sheet with Australia-based Orbit2Orbit to conduct a spaceflight study evaluating NorthStrive Biosciences' muscle-preservation therapeutics (EL-22 and EL-32) in microgravity. The multi-part relationship includes a Mice2Space research collaboration, a U.S. aerospace manufacturing partnership with A&B Aerospace, and a planned CAD $200,000 strategic investment by PMGC in Orbit2Orbit ahead of its proposed Canadian Securities Exchange listing.